Moderna’s First mRNA Mpox Vaccine Beats Licensed Rival Shots In Early Testing
September 4, 2024
Moderna's experimental mRNA mpox vaccine has outperformed existing licensed vaccines in a groundbreaking study published in Cell. The vaccine demonstrated superior efficacy in reducing symptoms and potentially limiting transmission, marking a significant advancement in mpox prevention.
This peer-reviewed research, led by Moderna virology researcher Alec Freyn, represents the first direct comparison between an mRNA vaccine and the licensed Bavarian Nordic MVA vaccine (marketed as Jynneos, Imvamune, and Imvanex) in nonhuman primates.
Moderna's experimental mRNA mpox vaccine has outperformed existing licensed vaccines in a groundbreaking study published in Cell. The vaccine demonstrated superior efficacy in reducing symptoms and potentially limiting transmission, marking a significant advancement in mpox prevention.
This peer-reviewed research, led by Moderna virology researcher Alec Freyn, represents the first direct comparison between an mRNA vaccine and the licensed Bavarian Nordic MVA vaccine (marketed as Jynneos, Imvamune, and Imvanex) in nonhuman primates.
The results are particularly timely given the escalating mpox outbreak in Africa, positioning Moderna's vaccine as a potential game-changer in global efforts to contain the disease and showcasing the company's capabilities beyond COVID-19 vaccines.